Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low-nanomolar affinity

Proteins: Structure, Function and Bioinformatics

Volumn 77, Issue 2, 2009, Pages 359-369

  Kimura, Richard H ^a,b   Levin, Aron M ^a   Cochran, Frank V ^a   Cochran, Jennifer R ^a,c  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Alternative scaffolds; Directed evolution; Integrin binding peptides; Protein engineering; RGD; Tumor targeting agents; Yeast surface display

Indexed keywords

ALPHAVBETA5 INTEGRIN; AMINO ACID; ANTINEOPLASTIC AGENT; ECBALLIUM ELATERIUM TRYPSIN INHIBITOR II; FIBRONECTIN; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; CELL ADHESION; CELL LINE, TUMOR; CYSTINE; DIRECTED MOLECULAR EVOLUTION; HUMANS; INTEGRIN ALPHA5BETA1; INTEGRIN ALPHAVBETA3; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PROTEIN ENGINEERING; RECEPTORS, VITRONECTIN; TRYPSIN INHIBITORS;

ECBALLIUM ELATERIUM;

EID: 70349462873     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22441     Document Type: Article

References (59)

1. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
2. Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 2006;13:113-135. (Pubitemid 44173112)
3. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-571.
4. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 2000;156:1345-1362. (Pubitemid 30660012)
5. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999;222:124-138. (Pubitemid 29514126)
6. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol 2004;64:207-238.
7. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
8. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715. (Pubitemid 26422728)
9. Haubner R, Finsinger D, Kessler H. Stereoisomeric peptide libaries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew Chem Int Ed 1997;36:1374-1389. (Pubitemid 27369766)
10. Haas TA, Plow EF. Integrin-ligand interactions: a year in review. Curr Opin Cell Biol 1994;6:656-662.
11. Healy JM, Murayama O, Maeda T, Yoshino K, Sekiguchi K, Kikuchi M. Peptide ligands for integrin alpha v beta 3 selected from random phage display libraries. Biochemistry 1995;34:3948-3955.
12. Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem 1993;268:20205-20210.
13. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol 1994;124:373-380.
14. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (NY) 1995;13:265-270.
15. Curley GP, Blum H, Humphries MJ. Integrin antagonists. Cell Mol Life Sci 1999;56:427-441.
16. Mikecz K. Vitaxin applied molecular evolution. Curr Opin Invest Drugs 2000;1:199-203.
17. Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, Emmell E, Giles-Komar J, Nakada MT. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004;110:326-335. (Pubitemid 38649882)
18. Pallaghy PK, Nielsen KJ, Craik DJ, Norton RS. A common structural motif incorporating a cystine knot and a triple-stranded beta-sheet in toxic and inhibitory polypeptides. Protein Sci 1994;3:1833-1839.
19. Chiche L, Heitz A, Gelly JC, Gracy J, Chau PT, Ha PT, Hernandez JF, Le-Nguyen D. Squash inhibitors: from structural motifs to macrocyclic knottins. Curr Protein Pept Sci 2004;5:341-349. (Pubitemid 39200164)
20. Craik DJ, Daly NL, Waine C. The cystine knot motif in toxins and implications for drug design. Toxicon 2001;39:43-60. (Pubitemid 30628928)
21. Boder ET, Wittrup KD. Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol 2000;328:430-444.
22. Gai SA, Wittrup KD. Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol 2007;17:467-473. (Pubitemid 47454774)
23. Favel A, Mattras H, Coletti-Previero MA, Zwilling R, Robinson EA, Castro B. Protease inhibitors from Ecballium elaterium seeds. Int J Pept Protein Res 1989;33:202-208. (Pubitemid 19095142)
24. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006;1:755-768.
25. Cheng Z, Wu Y, Xiong Z, Gambhir SS, Chen X. Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem 2005;16:1433-1441.
26. Orlando RA, Cheresh DA. Arginine-glycine-aspartic acid binding leading to molecular stabilization between integrin alpha v beta 3 and its ligand. J Biol Chem 1991;266:19543-19550.
27. Richards J, Miller M, Abend J, Koide A, Koide S, Dewhurst S. Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin. J Mol Biol 2003;326:1475-1488. (Pubitemid 36269089)
28. Kratzner R, Debreczeni JE, Pape T, Schneider TR, Wentzel A, Kolmar H, Sheldrick GM, Uson I. Structure of Ecballium elaterium trypsin inhibitor II (EETI-II): a rigid molecular scaffold. Acta Crystallogr D Biol Crystallogr 2005;61:1255-1262. (Pubitemid 43961297)
29. Christmann A, Walter K, Wentzel A, Kratzner R, Kolmar H. The cystine knot of a squash-type protease inhibitor as a structural scaffold for Escherichia coli cell surface display of conformationally constrained peptides. Protein Eng 1999;12:797-806. (Pubitemid 29472087)
30. Hilpert K, Wessner H, Schneider-Mergener J, Welfle K, Misselwitz R, Welfle H, Hocke AC, Hippenstiel S, Hohne W. Design and characterization of a hybrid miniprotein that specifically inhibits porcine pancreatic elastase. J Biol Chem 2003;278:24986-24993. (Pubitemid 37548660)
31. Krause S, Schmoldt HU, Wentzel A, Ballmaier M, Friedrich K, Kolmar H. Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists. Febs J 2007;274:86-95. (Pubitemid 44952900)
32. Reiss S, Sieber M, Oberle V, Wentzel A, Spangenberg P, Claus R, Kolmar H, Losche W. Inhibition of platelet aggregation by grafting RGD and KGD sequences on the structural scaffold of small disulfiderich proteins. Platelets 2006;17:153-157. (Pubitemid 43791626)
33. Wentzel A, Christmann A, Kratzner R, Kolmar H. Sequence requirements of the GPNG beta-turn of the Ecballium elaterium trypsin inhibitor II explored by combinatorial library screening. J Biol Chem 1999;274:21037-21043. (Pubitemid 129519607)
34. Kumar CC, Nie H, Rogers CP, Malkowski M, Maxwell E, Catino JJ, Armstrong L. Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor. J Pharmacol Exp Ther 1997;283:843-853. (Pubitemid 27514647)
35. Marcinkiewicz C, Vijay-Kumar S, McLane MA, Niewiarowski S. Significance of RGD loop and C-terminal domain of echistatin for recognition of alphaIIb beta3 and alphav beta3 integrins and expression of ligand-induced binding site. Blood 1997;90:1565-1575. (Pubitemid 27355429)
36. Wierzbicka-Patynowski I, Niewiarowski S, Marcinkiewicz C, Calvete JJ, Marcinkiewicz MM, McLane MA. Structural requirements of echistatin for the recognition of alphav beta3 and alpha5 beta1 integrins. J Biol Chem 1999;274:37809-37814.
37. Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, Chen X. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med 2006;47:113-121.
38. Cai W, Gambhir SS, Chen X. Multimodality tumor imaging targeting integrin alphavbeta3. Biotechniques 2005;39:S6-S17.
39. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharmacol 2006;3:472-487.
40. Bruning A, Runnebaum IB. CAR is a cell-cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFalpha, and TGFbeta. Gene Ther 2003;10:198-205.
41. Pfaff M, McLane MA, Beviglia L, Niewiarowski S, Timpl R. Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins alpha IIb beta 3, alpha V beta 3 and alpha 5 beta 1 and in cell adhesion inhibition. Cell Adhes Commun 1994;2:491-501.
42. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986;231:1559-1562. (Pubitemid 16050725)
43. Baggio R, Burgstaller P, Itale SP, Putney AR, Lane M, Lipovsek D, Wright MC, Roberts RW, Liu R, Szostak JW, Wagner RW. Identification of epitope-like consensus motifs using mRNA display. J Mol Recognit 2002;15:126-134. (Pubitemid 34895939)
44. Werle M, Schmitz T, Huang HL, Wentzel A, Kolmar H, Bernkop-Schnurch A. The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery. J Drug Target 2006;14:137-146. (Pubitemid 43878822)
45. Aota S, Nomizu M, Yamada KM. The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J Biol Chem 1994;269:24756-24761. (Pubitemid 24311733)
46. Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des 2006;12:2723-2747. (Pubitemid 44184633)
47. Tucker GC. Integrins: molecular targets in cancer therapy. Curr Oncol Rep 2006;8:96-103.
48. Kimura RH, Cheng Z, Gambhir SS, Cochran JR. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 2009;69:2435-2442.
49. Smith JW, Tachias K, Madison EL. Protein loop grafting to construct a variant of tissue-type plasminogen activator that binds platelet integrin alpha IIb beta 3. J Biol Chem 1995;270:30486-30490. (Pubitemid 26005106)
50. Yamada T, Matsushima M, Inaka K, Ohkubo T, Uyeda A, Maeda T, Titani K, Sekiguchi K, Kikuchi M. Structural and functional analyses of the Arg-Gly-Asp sequence introduced into human lysozyme. J Biol Chem 1993;268:10588-10592. (Pubitemid 23150249)
51. Hufton SE, van Neer N, van den Beuken T, Desmet J, Sablon E, Hoogenboom HR. Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands. FEBS Lett 2000;475:225-231. (Pubitemid 30408458)
52. Li R, Hoess RH, Bennett JS, DeGrado WF. Use of phage display to probe the evolution of binding specificity and affinity in integrins. Protein Eng 2003;16:65-72. (Pubitemid 36407066)
53. Gilbreth RN, Esaki K, Koide A, Sidhu SS, Koide S. A dominant conformational role for amino acid diversity in minimalist protein-protein interfaces. J Mol Biol 2008;381:407-418.
54. Hackel BJ, Kapila A, Wittrup KD. Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol 2008;381:1238-1252.
55. Koide A, Gilbreth RN, Esaki K, Tereshko V, Koide S. High-affinity single-domain binding proteins with a binary-code interface. Proc Natl Acad Sci USA 2007;104:6632-6637. (Pubitemid 47175552)
56. Lipovsek D, Lippow SM, Hackel BJ, Gregson MW, Cheng P, Kapila A, Wittrup KD. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J Mol Biol 2007;368:1024-1041. (Pubitemid 46584683)
57. Silverman AP, Levin AM, Lahti JL, Cochran JR. Engineered cystine-knot peptides that bind alphav beta3 integrin with antibody-like affinities. J Mol Biol 2009;385:1064-1075.
58. Heitz A, Avrutina O, Le-Nguyen D, Diederichsen U, Hernandez F, Gracy J, Kolmar H, Chiche L. Knottin cyclization: Impact on structure and dynamics. BMC Struct Biol 2008;8:54-71.
59. Barbas CF, Languino LR, Smith JW. High-affinity self-reactive human antibodies by design and selection: Targeting the integrin ligand binding site. Proc Natl Acad Sci 1993;90:10003-10007. (Pubitemid 23328239)